Topotecan (Hycamtin)

Indications

  • Cervical Cancer (see Cervical Cancer, [[Cervical Cancer]])
  • Ovarian Cancer (see Ovarian Cancer, [[Ovarian Cancer]])
  • Pediatric Sarcoma
  • Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]]): approved as single-agent chemotherapy for recurrent disease -> 20% response rate

Pharmacology

  • Oral Topoisomerase I Inhibitor: camptothecin derivative

Metabolism

  • xxxx

Administration

  • xxx

Dose Adjustment

  • Hepatic
  • Renal

Adverse Effects

Hematologic Adverse Effects

  • Myelosuppression
    • Anemia (see Anemia, [[Anemia]]): 33% of cases
    • Leukopenia (see Leukopenia, [[Leukopenia]]): 90% of cases
    • Thrombocytopenia (see Thrombocytopenia, [[Thrombocytopenia]]): 55% of cases

Pulmonary Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx
  • xxx
  • xxx

References

  • Rossi SE. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259
  • Topotecan-induced Bronchiolitis. Southern Medical Journal: July 2004 – Volume 97 – Issue 7 – pp 699-701